Home›Nephrology› Non-invasive vagus nerve stimulation reduces monthly headache days in migraine patients
Non-invasive vagus nerve stimulation reduces monthly headache days in migraine patientsTrial Shows Vagus Nerve Stimulation Reduces Migraine Frequency
Frontiers in MedicinePublished July 28, 2026Study authors: Chenjie Qian, Yuebinquan Shi, Chunhua Liu, Zegen Ye, Yue Jin, Huaqiang Wang, Di LiDOI ↗Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Consider nVNS as a non-pharmacological option for migraine, but long-term efficacy and safety are not yet established.
This meta-analysis evaluated the efficacy of non-invasive vagus nerve stimulation (nVNS) for migraine treatment and prevention, pooling data from 917 patients across multiple studies. The primary outcomes assessed were monthly headache days, monthly acute medication use, and headache pain intensity. Secondary outcomes included acute pain-free and pain-relief responses within 2 hours.
The analysis found that nVNS significantly reduced monthly headache days (MD = -1.52, 95% CI -1.86 to -1.18). Reductions in acute medication use and headache pain intensity were also reported, though effect sizes were not provided. Additionally, acute pain-free and pain-relief responses within 2 hours improved.
The authors note that further high-quality studies are needed to confirm long-term efficacy and safety. Adverse events, serious adverse events, and discontinuations were not reported in the meta-analysis. The findings suggest nVNS may be a promising non-pharmacological option for migraine, but clinicians should interpret results cautiously given the lack of long-term data and unreported safety details.
How this fits prior evidence
This meta-analysis extends prior evidence on non-invasive vagus nerve stimulation by providing pooled effect estimates for migraine outcomes. Prior coverage highlighted that transcutaneous vagus nerve stimulation uses distinct auricular and cervical pathways, and this analysis supports nVNS as a potential non-pharmacological option. It also addresses a gap in pharmacological prophylaxis, where 30% of pediatric patients report adverse events, by offering a non-drug alternative. However, long-term efficacy and safety remain unconfirmed, contrasting with the need for robust data seen with CGRP inhibitors.
A review of several studies involving 917 patients found that non-invasive vagus nerve stimulation (nVNS) can help manage migraine symptoms. The analysis showed that people using this method had fewer headache days each month compared to those who did not use it. It also led to a reduction in the amount of acute medication used for pain.
In addition to fewer headaches, patients reported lower levels of pain intensity during attacks. Some participants also saw improvements in how quickly their pain was relieved or eliminated within two hours of treatment. These results suggest that nVNS could be a helpful non-drug option for both treating and preventing migraines.
Because this is a meta-analysis of existing trials, the evidence is still developing. The study did not provide specific data on long-term safety or side effects. More high-quality research is needed to confirm how well this treatment works over time and to ensure it remains safe for all patients.
What this means for you:
nVNS may reduce migraine frequency and pain intensity, but more studies are needed to confirm long-term safety.
Common questions
What are the main benefits of using vagus nerve stimulation for migraines?
The study found that non-invasive vagus nerve stimulation (nVNS) significantly reduced the number of monthly headache days. It also helped lower the intensity of headache pain and decreased how much acute medication patients needed to take. Some users saw faster pain relief within two hours.
Is vagus nerve stimulation a safe alternative to medication?
nVNS is considered a promising non-pharmacological option for migraine treatment. However, because this specific review did not report on side effects or long-term safety data, you should talk to your doctor to see if it is the right choice for your specific health needs.
How quickly does vagus nerve stimulation work during a migraine?
The study reported improved results for both pain-free responses and general pain relief within 2 hours of using non-invasive vagus nerve stimulation. This suggests it may provide relatively quick relief during an acute attack.
Non-invasive vagus nerve stimulation (nVNS) has emerged as a potential non-pharmacological intervention for migraine. This systematic review and meta-analysis of randomized controlled trials (RCTs) evaluated its efficacy for both acute and preventive migraine treatment.
This review was conducted according to PRISMA and registered in PROSPERO (CRD420261347799). PubMed, Cochrane Central, Embase, CNKI, VIP, and Wanfang were searched from inception to February 19, 2026, to identify RCTs of nVNS for migraine. The primary outcomes were monthly headache days, monthly acute medication use, and headache pain intensity. Continuous outcomes were synthesized as mean differences (MDs), and dichotomous outcomes as odds ratios (ORs), with 95% confidence intervals (CIs). Fixed- or random-effects models were applied according to outcome type and statistical heterogeneity, and random-effects sensitivity analyses were conducted for continuous primary outcomes to account for expected clinical heterogeneity. Risk of bias was assessed using the original Cochrane Risk of Bias tool, and certainty of evidence was evaluated using GRADE.
Seven RCTs involving 917 patients with migraine were included. Meta-analysis showed that nVNS significantly reduced monthly headache days (MD = −1.52, 95% CI − 1.86 to −1.18, p
nVNS may reduce monthly headache days, acute medication use, and headache pain intensity, while also improving acute pain-free and pain-relief responses within 2 h in patients with migraine. It may represent a promising non-pharmacological option for migraine treatment and prevention, although further high-quality studies are needed to confirm its long-term efficacy and safety.
https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD420261347799, identifier: CRD420261347799.
